收藏切换
Pacritinib: a new Janus activated kinase 2/Fms-like tyrosine kinase 3 inhibitor for the treatment of myelofibrosis
收藏切换
PDF
Yong-yi WANG1, Lu HUANG2, 3, Xue-mei JI4
Chinese Journal of New Drugs | 2023, 32(10) : 994 - 999
Less
收藏切换
Chinese Journal of New Drugs | 2023, 32(10): 994-999
Pacritinib: a new Janus activated kinase 2/Fms-like tyrosine kinase 3 inhibitor for the treatment of myelofibrosis
Full
Yong-yi WANG1, Lu HUANG2, 3, Xue-mei JI4
Affiliations
  • 1School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China
  • 2School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205, China
  • 3School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China
  • 4College of Life Sciences and Technology, China Pharmaceutical University, Nanjing 211198, China
Published: 2023-05-30
Outline
收藏切换

Myelofibrosis (MF) is a myeloproliferative neoplasms (MPN), usually accomplies with thrombocytopenia, severely impacts the life quality of patients and presents a risk for leukemic transformation. Pacritinib is a kind of Janus activated kinase 2 (JAK2) and Fms-like tyrosine kinase 3 (FLT3) inhibitor. U.S. FDA has granted accelerated approval for pacritinib capsules (Vonjo), on Feb 28, 2022, in the treatment of adult patients with the platelet (blood clotting cells) levels below 50 000·μL-1 who have a rare form of bone marrow disorder known as intermediate or high-risk primary and secondary myelofibrosis. The oral dose of 200 mg twice daily showed good clinical efficacy and manageable safety. In this paper, the mechanism of action, pharmacodynamics, pharmacokinetics, safety, and clinical efficacy of daridorexant are reviewed.

myelofibrosis  /  Janus activated kinase 2/Fms-like tyrosine kinase 3 inhibitor  /  pacritinib  /  myeloproliferative neoplasms  /  thrombocytopenia  /  clinical effect  /  safety
Yong-yi WANG, Lu HUANG, Xue-mei JI. Pacritinib: a new Janus activated kinase 2/Fms-like tyrosine kinase 3 inhibitor for the treatment of myelofibrosis[J]. Chinese Journal of New Drugs, 2023 , 32 (10) : 994 -999 .
Year 2023 volume 32 Issue 10
PDF
32
11
Cite this Article
BibTeX
Article Info
  • Online Date:2026-03-05
  • Published:2023-05-30
Article Data
Affiliations
History
  • Accepted:2022-07-18
Affiliations
    1School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China
    2School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205, China
    3School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China
    4College of Life Sciences and Technology, China Pharmaceutical University, Nanjing 211198, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT